Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcriptomic Analysis of Omalizumab Add-on in Allergic Asthma
NCT06869382Phase 4Completed
- Sponsor
- Buddhist Tzu Chi Medical Foundation
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Buddhist Tzu Chi Medical Foundation. Started Jan 2023; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT06869382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869382.